A Study of Hospital-at-Home for People Receiving Tarlatamab

Inclusion Criteria:

Patient

• Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)

• Treatment plan of commercially available tarlatamab monotherapy as standard of care

• Patients must be 18 years of age or older

• Eastern Cooperative Oncology Group (ECOG) performance status <2

• Patients must have adequate organ and bone marrow function, defined by the followinglaboratory results obtained within 28 days prior to the first study treatment:

• ANC ≥ 1000 cells/μL (without granulocyte colony stimulating factor supportwithin 4 weeks prior to Cycle 1, Day 1)

• Platelet count ≥50,000/μL (without transfusion within 4 weeks prior to Cycle 1,Day 1)

• Hemoglobin ≥8.0 g/dL (without transfusion within 4 weeks prior to Cycle 1, Day

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3 X upperlimit of normal (ULN). Serum bilirubin ≤ 1.5 x ULN. Patients with known Gilbertdisease who have serum bilirubin level ≤ 2 x ULN may be enrolled.

• Estimated Glomerular Filtration Rate (eGFR) ≥ 30mL/min using the CKD-EPIformula.

• The patient is willing to give and sign informed consent

• Appropriate homebound setting as defined by one of the following:

• Lodging at MSK Residence or hotel

• 5 New York City boroughs, lower Westchester County (northern boundary CrossCounty Parkway) and Nassau County (eastern boundary Wantagh State Parkway).This is based on the community paramedic (SeniorCare) 60-minute response timecatchment area. If there is any uncertainty about patient residenceeligibility, the Principal Investigator will decide after discussion withSeniorCare.

• Patients must be accompanied by a caregiver for the period of time the patient isenrolled in the HaH intervention. For cases where there is uncertainty, thePrincipal Investigator will make the final determination.

Caregiver

• Primary caregiver as identified by patient enrolled on study

Physician

• Treating physician for patient(s) enrolled on study; managing treatment plan ofcommercially available tarlatamab as standard of care

Exclusion Criteria:

Patient

• Patients with a documented active infection prior to starting tarlatamab. Thisincludes grade 3 or higher viral, bacterial, or fungal infection.

• Patients with baseline dementia or cognitive barriers

• Uncontrolled arrhythmias

Caregiver

• Caregiver deemed inappropriate by treating physician

Physician

• No exclusion criteria